Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
#What Is The Projected Market Size Of The Treatment-Resistant Depression Market By 2029?
The treatment-resistant depression market has shown significant growth in recent years. It is anticipated to increase from $1.76 billion in 2024 to $1.87 billion in 2025, achieving a compound annual growth rate (CAGR) of 6.5%. This historical expansion can be attributed to several factors, including a rise in treatment-resistant depression cases, a growing incidence of depression, enhanced access to healthcare facilities, increased awareness regarding available treatment options, and the high prevalence of various mental disorders.
The market size for treatment-resistant depression is anticipated to undergo significant expansion in the upcoming years. It is projected to achieve a value of $2.44 billion by 2029, growing at a compound annual growth rate (CAGR) of 6.8%. This growth throughout the forecast period is attributable to an increase in chronic diseases, the increasing prevalence of anxiety disorders, a growing awareness of mental health, an increase in government initiatives, and a rise in healthcare expenditure. Noteworthy trends during this period include telemedicine and digital health expansion, advancements in diagnostic and therapeutic technologies, mental health awareness and stigma reduction, the adoption of personalized medicine, and the use of artificial intelligence.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23546&type=smp
Which Factors And Drivers Are Influencing The Treatment-Resistant Depression Market In 2025?
The widespread occurrence of mental disorders is anticipated to propel the growth of the treatment-resistant depression market moving forward. These conditions encompass a broad spectrum of states affecting an individual’s cognitive, emotional, and behavioral functions, often resulting in significant distress and impaired daily living. The high prevalence of mental disorders is influenced by factors such as genetic predisposition, as inherited genetic variations can impact brain chemistry and increase susceptibility to conditions like depression, anxiety, and schizophrenia. Treatment-resistant depression (TRD) provides support to mental disorder patients by encouraging more personalized and advanced treatments when standard therapies are ineffective, thus improving their chances of recovery and quality of life. For instance, in November 2023, the American Psychological Association (APA) reported that adults aged 18 to 34 had the highest rate of mental illnesses at 50% in 2023, while those aged 35 to 44 experienced the largest increase in diagnoses, with 45% reporting a mental illness. Consequently, the high prevalence of mental disorders is driving the growth of the treatment-resistant depression market.
Which Key Segments Fueling The Treatment-Resistant Depression Market?
The treatment-resistant depressionmarket covered in this report is segmented –
1) By Drug Class: Selective Serotonin Reuptake Inhibitors (SSRIS); Monoamine Oxidase Inhibitors; Tricyclic Antidepressant; Psychedelics; Other Drug Classes
2) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
4) By End-User: Hospitals; Homecare; Specialty Clinics; Other End-Users
Subsegments:
1) Selective Serotonin Reuptake Inhibitors (SSRIs): Fluoxetine; Sertraline; Paroxetine; Citalopram; Escitalopram
2) Monoamine Oxidase Inhibitors (MAOIs): Phenelzine; Tranylcypromine; Isocarboxazid; Selegiline
3) Tricyclic Antidepressants (TCAs): Amitriptyline; Nortriptyline; Imipramine; Clomipramine; Doxepin
4) Psychedelics: Ketamine; Esketamine; Psilocybin; Lysergic Acid Diethylamide (LSD); 3,4-Methylenedioxymethamphetamine (MDMA); Other Drug Classes
5) Atypical Antipsychotics: Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs); Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs); Glutamate Modulators; Hormonal Therapies
What Are The Major Trends Driving The Growth Of The Treatment-Resistant Depression Market?
Leading enterprises within the treatment-resistant depression market are concentrating on creating novel therapies, particularly monotherapy, to fulfill outstanding patient requirements, enhance effectiveness, and minimize adverse reactions. Monotherapy involves administering a singular treatment or drug for a condition, as opposed to employing multiple treatments concurrently. This approach aids in managing treatment-resistant depression by providing a concentrated, individual therapy that could prove more successful for individuals who have not shown improvement with various other medications. As an illustration, in January 2025, Johnson & Johnson Services Inc., a pharmaceutical, biotechnology, and medical technology firm based in the US, publicized the U.S. Food and Drug Administration (FDA), a US-based governmental regulatory organization, approval of SPRAVATO (esketamine) nasal spray, which is a rapidly effective therapy for adults suffering from treatment-resistant depression (TRD). SPRAVATO is prescribed in conjunction with an oral antidepressant when individuals have not sufficiently responded to a minimum of two prior antidepressant treatments. The swift impact of this medication addresses shortcomings found in conventional antidepressants, which frequently require several weeks to demonstrate any noticeable effects. Being derived from ketamine, esketamine operates by targeting the brain’s NMDA receptors, with the potential to elevate mood within mere hours. This approval represented a considerable breakthrough in the domain of mental health care.
Which Global Market Leaders Are Shaping The Future Of The Treatment-Resistant Depression Sector?
Major companies operating in the treatment-resistant depression market are Pfizer Inc., Johnson & Johnson Services Inc., Abbott Laboratories, Novartis AG, GlaxoSmithKline (GSK) plc., Hikma Pharmaceuticals plc, Neurocrine Biosciences Inc., Relmada Therapeutics Inc., Neuronetics Inc., COMPASS Pathways, Lykos Therapeutics, Reviva Pharmaceuticals, Celon Pharma SA, BrainsWay Ltd., Magstim Company Limited, MindMed, Alto Neuroscience, Sage Therapeutics Inc., MindBio Therapeutics Ltd., Reunion Neuroscience
Download The Full Report For Exclusive Market Findings:
Which Region Is Expected To Witness The Fastest Growth In The Treatment-Resistant Depression Market?
North America was the largest region in the treatment-resistant depression market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the treatment-resistant depression market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Treatment-Resistant Depression Market Report:
https://www.thebusinessresearchcompany.com/customise?id=23546&type=smp
Browse Through More Reports Similar to the Global Treatment-Resistant Depression Market 2025, By The Business Research Company
Antidepressant Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/antidepressant-global-market-report
Postpartum Depression Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/postpartum-depression-global-market-report
Major Depressive Disorder Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/major-depressive-disorder-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model